My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 611

    1.

    Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.

    Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL.

    Ann Intern Med. 2005 Feb 1;142(3):157-64.PMID: 15684203 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.

    Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.

    Arch Intern Med. 2005 May 9;165(9):978-84.PMID: 15883235 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.

    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.

    Circulation. 2006 Jun 27;113(25):2906-13. Epub 2006 Jun 19.PMID: 16785336 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.

    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.

    Circulation. 2004 May 4;109(17):2068-73. Epub 2004 Apr 19.PMID: 15096449 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.

    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA.

    Lancet. 2005 Feb 5-11;365(9458):475-81.PMID: 15705456 [PubMed - indexed for MEDLINE]Related articles

    6.

    Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.

    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.

    Arthritis Rheum. 2006 Nov;54(11):3390-8.PMID: 17075817 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.

    Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.

    Drug Saf. 2006;29(7):621-32.PMID: 16808554 [PubMed - indexed for MEDLINE]Related articles

    8.

    Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.

    Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A.

    Arch Intern Med. 2003 Feb 24;163(4):481-6.PMID: 12588209 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.

    Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.

    Pharmacoepidemiol Drug Saf. 2007 May;16(5):493-503.PMID: 17086567 [PubMed - indexed for MEDLINE]Related articles

    10.

    Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.

    Rahme E, Nedjar H.

    Rheumatology (Oxford). 2007 Mar;46(3):435-8. Epub 2007 Jan 25.PMID: 17255138 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

    McGettigan P, Henry D.

    JAMA. 2006 Oct 4;296(13):1633-44. Epub 2006 Sep 12. Review.PMID: 16968831 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.

    Lévesque LE, Brophy JM, Zhang B.

    Ann Intern Med. 2005 Apr 5;142(7):481-9.PMID: 15809459 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.

    Chen LC, Ashcroft DM.

    Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):762-72.PMID: 17457957 [PubMed - indexed for MEDLINE]Related articles

    14.

    Factors associated with celecoxib and rofecoxib utilization.

    Rawson NS, Nourjah P, Grosser SC, Graham DJ.

    Ann Pharmacother. 2005 Apr;39(4):597-602. Epub 2005 Mar 8.PMID: 15755796 [PubMed - indexed for MEDLINE]Related articles

    15.

    Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.

    Lévesque LE, Brophy JM, Zhang B.

    CMAJ. 2006 May 23;174(11):1563-9. Epub 2006 May 2.PMID: 16670396 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.

    Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA.

    Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):266-74.PMID: 16611201 [PubMed - indexed for MEDLINE]Related articles

    17.

    Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.

    Spalding WM, Reeves MJ, Whelton A.

    Am J Ther. 2007 Jan-Feb;14(1):3-12.PMID: 17303969 [PubMed - indexed for MEDLINE]Related articles

    18.

    Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.

    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.

    Am J Manag Care. 2002 Oct;8(15 Suppl):S414-27.PMID: 12416791 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.

    Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA.

    Drug Saf. 2005;28(9):803-16.PMID: 16119973 [PubMed - indexed for MEDLINE]Related articles

    20.

    Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.

    Hippisley-Cox J, Coupland C.

    BMJ. 2005 Jun 11;330(7504):1366.PMID: 15947398 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity